Articles
Filter tips : A case study on separation performance
This study describes an experimental set-up that allows filter tips to be tested for their separation performance in relation to aerosols
[ + ]Screening drugs of abuse by LC/MS
High throughput screening of drugs of abuse is performed at St Olav Hospital by LC/MS. Typically done by immunoassay, this overview describes the procedures for using this highly selective and quantitative LC/MS methodology
[ + ]Get ready for a sugar rush
In 2000, a research team led by University of Queensland molecular geneticist Prof Robert Birch first inserted a gene from the plant-dwelling bacterium Pantoea dispersa into sugarcane cells, aiming to create plants that would synthesise isomaltulose, instead of sucrose. [ + ]
Fruits of the revolution
Queensland researchers are developing GM cultivars of three tropical crops - pineapple, papaw and banana, to solve disease and quality problems. [ + ]
Towards the carbohydrate economy
Sugar CRC CEO Dr Peter Twine sees the industry - with a little help from its friends in the research community - leading Australia into what he calls the 'carbohydrate economy'. [ + ]
GM research heads to warmer climes
The old joke about Queensland being a decade plus one hour behind the southern states during daylight saving is fast fading from the repertoire of state-vs-state humour. [ + ]
The big Australian biopharma
Brian McNamee has been at the helm of Australia's oldest - and now biggest - life-sciences company, CSL, for 15 years. He guided the company through its public listing in 1994 and has overseen its growth to a market capitalisation of $6.8 billion. He spoke with Melissa Trudinger about CSL's research and development programs, and his vision for the company's future. [ + ]
The near-term potential of stem cell therapies
The prospect of therapies based on human stem cells holds great promise for revolutionising the practice of medicine, says Silviu Itescu. [ + ]
A productive dose of medicines
The pressure of healthcare costs in the future will bring better health outcomes, predict Kieran Schneemann and Brendan Shaw. [ + ]
The commercial value and business of human ES cells
The human embryonic stem (ES) cell field is one of the most exciting and complex opportunities of today's biomedical industry, write Peter Mountford and Kenzo Nakajima. [ + ]
Industrial and commercial VOC quantification
Selected ion flow tube mass spectrometry (SIFT-MS) instruments represent the latest generation in the evolutionary path of analytical instruments. SIFT-MS is complementing existing GC-based analytical services as well as opening up entirely new services
[ + ]Making strange or making sense - art and the life sciences
Oron Catts and Ionat Zurr talk about the future with Bioart. [ + ]
ISPE aims to build bridges to biotech
An international conference to be held in Australia next week has particular relevance for the future of Australia's biotech and pharmaceutical industries, writes Iain Scott. [ + ]
The mammalian genome and phenome
Chris Goodnow talks about defining the mammalian phenome and how this may pan out in the future. [ + ]
The hard cell: research debate to fire up again
Melissa Trudinger looks at the issues that are set to arise as debate begins again on stem cell research in Australia. [ + ]
